首页/数据集/Grade 3 or 4 clinical events or laboratory abnormalities.

Grade 3 or 4 clinical events or laboratory abnormalities.

Figshare2019-02-01 更新2026-04-29 收录

临床试验安全性评估

不良事件严重程度分级

数据链接：

https://figshare.com/articles/dataset/Grade_3_or_4_clinical_events_or_laboratory_abnormalities_/7661933 数据链接链接失效反馈

官方服务：

资源简介：

Grade 3 or 4 clinical events or laboratory abnormalities.

应用场景：

创建时间：

2019-02-01

临床试验安全性评估

癌症风险统计模型

Abbreviations: mITT, modified intention to treat; NDA, New drug Approval; NMSC, non-melanoma skin cancers; OR, odds ratio; 95% CI, 95% confidence interval; *14 trials included for overall cancer analy

NIAID Data Ecosystem60

Frequency of AEs and maximum AE grade/subject after treatment by type of treatment and gender, October 2016−February 2017.

药物不良事件

临床试验安全性评估

Frequency of AEs and maximum AE grade/subject after treatment by type of treatment and gender, October 2016−February 2017.

NIAID Data Ecosystem40

Number (%) of subjects with adverse events by adverse event category, with Mazzotti reactions for which Fisher's exact text between at least one moxidectin treatment group and ivermectin treatment group yielded p-value<0.05 and for SSPH (mITT population).

药物不良反应监测

临床试验安全性评估

UnAE Adverse event unrelated to study drug or study participation. ADR Adverse drug reaction, MAZ Mazzotti reaction, MAP mean arterial pressure: Diastolic pressure+1/3 (Systolic pressure - Diastolic P

NIAID Data Ecosystem20

Safety outcomes in the patients who received an injection of the investigational product.

临床试验安全性评估

药物不良反应监测

Safety outcomes in the patients who received an injection of the investigational product.

Figshare2019-12-10 更新50

Number of subjects presenting possible or probable related adverse events.

药物不良事件

临床试验安全性评估

Number of subjects presenting possible or probable related adverse events.

NIAID Data Ecosystem40